Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?
Files
Publication date
2015-11-01
Authors
Arends, Joop E.
Lieveld, Faydra I.
Boeijen, Lauke L.
de Kanter, C T Klaartje
van Erpecum, Karel J.
Salmon, Dominique
Hoepelman, Andy
Asselah, Tarik
Ustianowski, Andrew
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Evidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted drug resistance.
Keywords
Direct-acting antiviral agents, Hepatitis C, HIV, Liver fibrosis, Pegylated interferon, Taverne, Hepatology, Journal Article, Review
Citation
Arends, J E, Lieveld, F I, Boeijen, L L, De Kanter, C T M M, van Erpecum, K J, Salmon, D, Hoepelman, A I M, Asselah, T & Ustianowski, A 2015, 'Natural history and treatment of HCV/HIV coinfection : Is it time to change paradigms?', Journal of Hepatology, vol. 63, no. 5, pp. 1254-1262. https://doi.org/10.1016/j.jhep.2015.06.034